Soon after, several pilot programs, including programs in Italy, Australia, Japan, Korea, USA, and Hungary, have tested the feasibility of Pompe newborn screening and understood the incidence of Pompe disease and the impact of the disease. After the Discretionary Advisory Committee on Heritable Disorders in Newborns and Children (DACHDNC) added Pompe disease to the Recommended Uniform Screening Panel (RUSP) in 2013, the spread of Pompe disease newborn screening increased. However, challenges remain, including sensitivity and specificity of the assays, management of pseudodeficiency, time and method to treat IOPD patients detected by screening, immunomodulation, and management of later-onset Pompe disease patients discovered by screening. In this special issue of the International Journal of Neonatal Screening, global experiences with Pompe disease newborn screening were pooled to enhance the understanding of screening and improve the outcomes of patients affected by Pompe disease. 
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